Stifel Nicolaus Issues Positive Forecast for Solventum (NYSE:SOLV) Stock Price

Solventum (NYSE:SOLV) had its target price boosted by investment analysts at Stifel Nicolaus from $90.00 to $100.00 in a report released on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Stifel Nicolaus’ price objective indicates a potential upside of 19.94% from the company’s previous close.

Several other research firms have also issued reports on SOLV. Wells Fargo & Company cut their target price on Solventum from $83.00 to $70.00 and set an “equal weight” rating on the stock in a research note on Wednesday, May 6th. KeyCorp restated an “overweight” rating and issued a $102.00 price target on shares of Solventum in a report on Thursday. BTIG Research boosted their price objective on shares of Solventum from $91.00 to $95.00 and gave the stock a “buy” rating in a research note on Thursday. Piper Sandler decreased their target price on shares of Solventum from $98.00 to $92.00 and set an “overweight” rating for the company in a research report on Friday, April 17th. Finally, UBS Group restated a “buy” rating and issued a $101.00 target price on shares of Solventum in a research note on Thursday. Seven research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $89.82.

Solventum Trading Down 4.7%

Solventum stock traded down $4.09 during midday trading on Thursday, reaching $83.38. The stock had a trading volume of 283,769 shares, compared to its average volume of 1,405,196. The company has a quick ratio of 0.75, a current ratio of 1.07 and a debt-to-equity ratio of 0.96. The firm has a market cap of $14.44 billion, a price-to-earnings ratio of 10.30, a price-to-earnings-growth ratio of 1.36 and a beta of 0.60. Solventum has a 52-week low of $62.38 and a 52-week high of $90.00. The company has a fifty day moving average of $79.09 and a 200 day moving average of $74.36.

Solventum (NYSE:SOLV) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $2.55 EPS for the quarter, topping analysts’ consensus estimates of $1.91 by $0.64. Solventum had a net margin of 17.33% and a return on equity of 23.51%. The firm had revenue of $2.21 billion for the quarter, compared to analysts’ expectations of $2.15 billion. During the same period in the prior year, the business posted $1.69 earnings per share. The business’s revenue for the quarter was up 2.2% on a year-over-year basis. Solventum has set its FY 2026 guidance at 7.100-7.200 EPS. On average, analysts anticipate that Solventum will post 6.58 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Solventum

Institutional investors and hedge funds have recently modified their holdings of the company. Assetmark Inc. lifted its holdings in Solventum by 21.4% in the fourth quarter. Assetmark Inc. now owns 725 shares of the company’s stock valued at $57,000 after acquiring an additional 128 shares during the last quarter. BOKF NA increased its stake in Solventum by 6.9% during the third quarter. BOKF NA now owns 2,193 shares of the company’s stock worth $160,000 after acquiring an additional 141 shares during the last quarter. Smartleaf Asset Management LLC increased its stake in Solventum by 23.6% during the fourth quarter. Smartleaf Asset Management LLC now owns 744 shares of the company’s stock worth $60,000 after acquiring an additional 142 shares during the last quarter. NewEdge Advisors LLC raised its position in Solventum by 2.2% in the first quarter. NewEdge Advisors LLC now owns 6,707 shares of the company’s stock valued at $438,000 after purchasing an additional 144 shares during the period. Finally, Deseret Mutual Benefit Administrators raised its position in Solventum by 39.5% in the fourth quarter. Deseret Mutual Benefit Administrators now owns 516 shares of the company’s stock valued at $41,000 after purchasing an additional 146 shares during the period.

Key Solventum News

Here are the key news stories impacting Solventum this week:

• Positive Sentiment: Quarterly results exceeded expectations. Solventum reported second-quarter adjusted earnings of $2.55 per share, well above the $1.91 analyst consensus and up from $1.69 a year earlier. Revenue reached $2.21 billion, topping the $2.15 billion estimate, while reported sales rose 2.2% and organic sales increased 9.5%. Solventum Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Full-year guidance was raised. Solventum increased its fiscal 2026 adjusted EPS outlook to $7.10-$7.20, above the roughly $6.55-$6.58 analyst expectation, while also raising its outlook for organic sales growth and free cash flow. Solventum outlines HIS separation and raises 2026 EPS guide
• Positive Sentiment: The HIS separation could unlock value. Management said it intends to separate its healthcare software business, allowing Solventum to focus on MedTech while giving HIS greater flexibility to pursue investment and growth as a standalone company. Solventum Announces Intent to Separate its Health Information Systems Business
• Negative Sentiment: Investors may be concerned about separation and execution risks. The HIS transaction, reportedly influenced by activist pressure, adds restructuring complexity and uncertainty over timing, costs, stranded expenses and the eventual value of the separated businesses. Solventum to hive off healthcare software business, raises profit forecast

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.